. 2020 Feb 12;73(5):434–444. doi: 10.4097/kja.19481

Table 2.

Antiallodynic Effect of Intrathecally Administered R-PIA against Mechanical Static Allodynia

Time (min)	0	15	30	45	60	90	120	180
Normal	15.0 ± 0.0	14.9 ± 0.1	15.0 ± 0.0	14.9 ± 0.1	14.9 ± 0.1	15.0 ± 0.0	15.0 ± 0.0	14.9 ± 0.1
V + S + S	1.8 ± 0.3^*	1.6 ± 0.4^*	2.2 ± 0.3^*	2.1 ± 0.4^*	1.6 ± 0.3^*	2.1 ± 0.4^*	1.8 ± 0.4^*	2.0 ± 0.4^*
V + S + R-PIA 0.3	2.4 ± 0.3^*	2.3 ± 0.5^*	2.5 ± 0.3^*	3.2 ± 0.3^*	3.6 ± 0.3^*	4.5 ± 0.3^*	2.8 ± 0.2^*	2.3 ± 0.2^*
V + DPCPX + R-PIA 0.3	2.3 ± 0.3^*	3.4 ± 0.5^*	2.7 ± 0.4^*	3.9 ± 0.4^*	4.2 ± 0.3^*	3.6 ± 0.3^*	2.8 ± 0.2^*	2.3 ± 0.2^*
V + S + R-PIA 1.0	1.8 ± 0.3^*	10.8 ± 0.8^*,†	10.1 ± 0.7^*,†	8.2 ± 0.5^*,†	8.4 ± 0.4^*,†	7.3 ± 0.4^*,†	5.0 ± 0.2^*,†	4.0 ± 0.2^*,†
V + DPCPX + R-PIA 1.0	1.9 ± 0.2^*	3.6 ± 0.4^*,‡	3.4 ± 0.3^*,‡	2.8 ± 0.5^*,‡	2.1 ± 0.1^*,‡	2.6 ± 0.4^*,‡	2.0 ± 0.3^*,‡	1.7 ± 0.2^*,‡
V + S + R-PIA 3.0	1.6 ± 0.3^*	14.5 ± 0.3^†	13.9 ± 0.7^†	13.1 ± 0.8^†	11.9 ± 0.8^*,†	11.3 ± 0.7^*,†	9.4 ± 0.4^*,†	8.3 ± 0.4^*,†
V + DPCPX + R-PIA 3.0	2.0 ± 0.2^*	3.9 ± 0.3^*,§	4.4 ± 0.3^*,§	3.8 ± 0.4^*,§	3.8 ± 0.3^*,§	3.3 ± 0.3^*,§	2.3 ± 0.2^*,§	2.1 ± 0.2^*,§

Peripheral neuropathy was induced by the administration of vincristine (100 μg/kg, i.p.) for 10 days. On the 28th day, saline or DPCPX (10 μg/10 μl) was intrathecally administered 15 min before intrathecal R-PIA administration (1.0 μg/10 μl or 3.0 μg/10 μl). Mechanical static allodynia was then assessed using the von Frey filament test (gram). Results are expressed as mean ± standard error of mean, n = 6 rats per group. One-way ANOVA followed by Tukey’s post hoc test.

P < 0.05 vs. normal control group,

^†

P < 0.05 vs. vincristine control group,

^‡

P < 0.05 vs. R-PIA 1.0 μg/10 μl group,

^§

P < 0.05 vs. R-PIA 3.0 μg/10 μl group. V: vincristine, S: saline, DPCPX: 1,3-dipropyl-8-cyclopentylxanthine = adenosine A₁ receptor antagonist, R-PIA: N6-(2-phenylisopropyl)-adenosine R-(-)isomer = adenosine A₁ receptor agonist.